(BRK.A), (BRK.B)
Lubrizol, a Berkshire Hathaway company and global leader in specialty chemicals, has signed a Memorandum of Understanding (MoU) with Polyhose, a global leader in fluid conveyance systems, to bolster innovation in India’s medical sector. The agreement was formalized in the presence of Tamil Nadu Industries Minister Dr. T.R.B. Rajaa and Industries Secretary V. Arun Roy.
The partnership aims to establish a state-of-the-art medical manufacturing facility in Tamil Nadu, increasing Lubrizol’s local medical tubing production by five times. This expansion will cater to domestic and international markets, producing high-quality tubing for critical neurovascular and cardiovascular applications such as balloon and minimally invasive catheters.
“This collaboration introduces precision manufacturing to India, opening new opportunities to serve critical care markets locally and globally,” said Bhavana Bindra, Lubrizol’s Managing Director for India, the Middle East, and Africa. The facility will use Lubrizol’s advanced thermoplastic polyurethane (TPU), known for its biocompatibility and high performance, and comply with ISO 13485 standards.
Lubrizol President and CEO Rebecca Liebert emphasized the company’s commitment to India’s growth, noting the country’s strategic role in its global operations. “This investment strengthens our local-for-local and local-for-global approach, ensuring access to world-class medical solutions,” she said.
The collaboration with Polyhose builds on a seven-year partnership and leverages Tamil Nadu’s industrial growth. Shabbir Y J, Managing Director of Polyhose, highlighted the state’s conducive environment for innovation and expansion.
The project is part of Lubrizol’s broader $350 million investment in India, which includes a Global Capability Center in Pune and major facilities in Gujarat and Aurangabad. Groundbreaking for the Tamil Nadu site is planned for 2025, with operations commencing in 2026.
© 2024 David Mazor
Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell the stock. The information contained in this article should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.